DOCSLIB.ORG

Reportable Infectious Diseases Reference Manual

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

REPORTABLE INFECTIOUS DISEASES REFERENCE MANUAL Routine Reportable Infectious Disease Follow-up for the State and Local Health Departments Connecticut Department of Public Health Infectious Diseases Section March 2016 Routine Reportable Disease Follow-up nual a seases i For State and Local Health Departments M D ble 2016 nce a e efer eport R R REPORTABLE INFECTIOUS DISEASES REFERENCE MANUAL Routine Reportable Infectious Disease Follow-up for the State and Local Health Departments Connecticut Department of Public Health Infectious Diseases Section March 2016 Connecticut Department of Public Health Public Health Initiatives Branch Infectious Diseases Section REPORTABLE INFECTIOUS DISEASES REFERENCE MANUAL Routine Reportable Infectious Disease Follow-up for the State and Local Health Departments March 2016 Table of Contents Introduction ........................................................................................................................7 Purpose of Reportable Infectious Diseases Reference Manual ...................................7 Reportable Infectious Disease Follow-up in Connecticut.............................................8 Reportable Diseases Listing.................................................................................8 Mandated Reporting ..............................................................................................8 Authority to Conduct Case Follow-up .................................................................8 Reportable Disease Follow-up by State and Local Health Departments ........9 Outbreak Investigations/Public Health Emergency Response Plan.. .......................12 What is Maven? ................................................................................................................14 What is FoodNet? ............................................................................................................14 What is FoodCORE? …………………………………………………………………………15 Confidentiality ................................................................................................................ 15 Health Insurance Portability and Accountability Act of 1996 .....................................17 Additional Resources for Control-Related Follow-up .................................................18 4 Section 1: Diseases Indicative of Bioterrorism Anthrax Ricin poisoning Botulism Smallpox Brucellosis Staphylococcal enterotoxin B pulmonary Glanders poisoning Melioidosis Tularemia Plague Venezuelan equine encephalitis Q Fever Viral hemorrhagic fever Section 2: Foodborne Diseases Botulism Listeriosis Campylobacteriosis Salmonellosis Cholera Shiga toxin-producing E. coli Cryptosporidiosis Shigellosis Cyclosporiasis Trichinosis Escherichia coli O157:H7 (see Shiga toxin- Typhoid/paratyphoid fever (Salmonella producing E. coli) Typhi/Paratyphi infection) Giardiasis Vibrio infections, non cholera Hemolytic uremic syndrome (HUS) Yersiniosis Hepatitis A infection Section 3: Sexually Transmitted Diseases Chancroid Neonatal Herpes (≤60 days) Chlamydia Syphilis Gonorrhea Section 4: Vaccine-Preventable Diseases Diphtheria Pertussis Haemophilus influenzae (invasive) Pneumococcal disease (invasive) Hepatitis B Poliomyelitis Influenza Rubella Measles Tetanus Meningococcal disease Varicella (chickenpox) Mumps 5 Section 5: Vectorborne Diseases Babesiosis Other Arbovirus California Group virus Rocky Mountain spotted fever Dengue St. Louis Encephalitis virus Eastern Equine encephalitis virus West Nile virus, animal or human Ehrlichiosis/Anaplasmosis Yellow Fever Lyme disease Malaria Section 6: Other Diseases of Public Health Significance Acquired Immunodeficiency Syndrome SARS-CoV (AIDS) Staphylococcus aureus disease Hansen’s Disease (Leprosy) (reduced/resistant susceptibility to vancomycin) Hepatitis C Staphylococcus aureus disease (invasive, Hepatitis Delta methicillin-resistant) HIV Staphylococcus epidermidis disease HPV (reduced/resistant susceptibility to vancomycin) Influenza Streptococcal infection (invasive groups A and B) Legionellosis Tuberculosis Rabies (animal and human) Vaccinia disease Rheumatic fever Section 7: Attachments Attachment A Reportable Diseases List Attachment B Confidential Disease Reporting Form (PD23) Laboratory Attachment C Reportable Significant Findings List Laboratory Attachment D Report of Significant Findings Form (OL15C) Attachment E Example of a Confidentiality Statement Attachment F General Foodborne Diseases Interview Form Attachment G Cholera and Other Vibrio Illness Surveillance Report Attachment H Hepatitis A Case Report Form Attachment I Hepatitis A Case Contact management form Attachment J Varicella Case Report Form Attachment K Typhoid Fever Surveillance Report Attachment L Dengue Case Report Form Attachment M DPH Cluster Investigation Protocol Attachment N DPH Ebola-Related Traveler Monitoring Protocols Attachment O Connecticut Zika Virus Surveillance and Response Plan 6 Introduction PURPOSE OF REPORTABLE INFECTIOUS DISEASES REFERENCE MANUAL The Connecticut Reportable Infectious Diseases Reference Manual contains the recommendations of the Infectious Diseases Section, Connecticut Department of Public Health (DPH) regarding the responsibilities of DPH and local health departments (LHDs) for routine reportable infectious disease case investigation and follow-up. Intended primary users are health directors, public health nurses, sanitarians, and other LHD personnel in Connecticut. The focus of this reference manual is on the routine follow-up of the reportable infectious diseases that are not covered by the STD/HIV/Hepatitis Programs or the Tuberculosis Program, which have their own disease-specific recommendations. This reference manual does not specifically address possible agents of bioterrorism, except by providing links to the Connecticut Public Health Emergency Response Plan and to the resources available on the Centers for Disease Control and Prevention (CDC) website. We recommend that all primary users of this reference manual have their own copies of the following resources: • Control of Communicable Diseases Manual, 20th Edition (American Public Health Association, David L. Heymann, MD, Editor); • Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Edition (American Academy of Pediatrics, Larry K. Pickering, MD, FAAP, Editor) We recommend that the primary users of this reference manual start their investigation of a reportable disease by reviewing the appropriate sections of these two primary sources. Much of the disease-specific information in this reference manual is derived from these two resources and from materials available on the CDC website: http://www.cdc.gov/. This reference manual is intended to provide supplemental information that will help public health practitioners in Connecticut implement nationally-recognized disease prevention and control measures for reportable infectious diseases. In this reference manual, diseases are categorized into the following sections: those indicative of bioterrorism, foodborne, sexually transmitted, vaccine- preventable, vectorborne, and other diseases of public health significance. Within each section, diseases are listed alphabetically. Within each disease topic, the user will find information for routine follow-up of reportable diseases, and a fact sheet. Section 7 contains forms and questionnaires for standardizing disease follow-up. Introduction 7 March 2016 REPORTABLE DISEASE FOLLOW-UP IN CONNECTICUT Reportable Diseases Listing Connecticut General Statutes (CGS) § 19a-2A and §s 19a-36-A2 of the Connecticut Public Health Code mandate the Commissioner of DPH to issue a list of reportable diseases and reportable laboratory findings on an annual basis. An advisory committee of public health officials, clinicians, and laboratorians contribute to the process. Mandated Reporting CGS § 19a-215b and §s 19a-36-A3 of the Public Health Code require that health care providers, including administrators of health care facilities, report the diseases listed in the List of Reportable Diseases (Attachment A). These reports are confidential (pursuant to CGS § 19a-25 and § 19a-215d,e) and fall into two categories: • Category 1: These diseases are reportable immediately by telephone on the day of recognition or strong suspicion. On weekdays, reports must be made to the DPH and LHD; on evenings and weekends, these reports must be made to the DPH. A Confidential Disease Report (PD-23) (Attachment B) or a disease-specific report form should be mailed to both the DPH and LHD within 12 hours. • Category 2: These diseases are reportable by mail within 12 hours of recognition or strong suspicion to both the DPH and LHD. Section 19a-36-A3 of the Public Health Code also requires that directors of clinical laboratories must report to DPH any laboratory evidence suggestive of diseases listed in the Laboratory Report of Significant Findings (Attachment C). A completed Form OL-15C (Attachment D) should be mailed to both the DPH and LHD of the town in which the patient resides. Authority to Conduct Case Follow-up CGS §19a-215d grants authority to the DPH and the LHD director or his/her authorized personnel to contact the reporting physician (if able to be located) and the person with a reportable condition for the purposes of disease control. All information collected, as part of this follow-up investigation, is considered confidential, pursuant to § 19a-25. Introduction 8 March 2016 Reportable Disease Follow-up by the State and Local Health Departments The following reflects the recommendations
Recommended publications
  • Melioidosis: a Clinical Model for Gram-Negative Sepsis

    Melioidosis: a Clinical Model for Gram-Negative Sepsis

    J. Med. Microbiol. Ð Vol. 50 2001), 657±658 # 2001 The Pathological Society of Great Britain and Ireland ISSN 0022-2615 EDITORIAL Melioidosis: a clinical model for gram-negative sepsis The recently published study of recombinant human clinical sepsis model over the current heterogeneous activated protein C drotrecogin-á, Eli Lilly, Indiana- clinical trials. Our knowledge of melioidosis and its polis, IN, USA) in severe sepsis makes welcome causative organism, Burkholderia formerly Pseudomo- reading. At last a clinical trial of an augmentative nas) pseudomallei, has expanded considerably over the therapy in severe sepsis has managed to show a last 15 years. Melioidosis was originally described in mortality bene®t from the trial agent [1]. Most studies Myanmar then Burma) in 1911 and came to of augmentative treatments in serious sepsis have failed prominence during the Vietnam con¯ict, when French to show clear bene®t. Sepsis studies commonly involve and American soldiers became infected. It has been a syndrome caused by a myriad of organisms, occurring described in most countries of south-east Asia, in a very heterogeneous group of patients, who may be including the Peoples Republic of China and the Lao enrolled in one of several centres. This introduces PDR [5], but Thailand has the greatest reported disease multiple confounding factors. Agood model for clinical burden [6]. It is also endemic to northern Australia [7]. sepsis studies would ideally cause disease in a relatively Understanding of the epidemiology of the disease has homogeneous population, be acquired in a community been improved by the demonstration of two pheno- setting, present in large numbers to a single institution, typically similar but genetically distinct biotypes in the be caused by a single organism, and ordinarily result in environment [8], only one of which appears to be a substantial mortality rate.
  • Communicable Diseases Monthly Newsletter

    Communicable Diseases Monthly Newsletter

    Communicable Diseases Monthly Newsletter October 2013 Volume 6, Issue 10 What is Pneumonia? neumonia is an infection of the lungs that is Inside This Issue P usually caused by bacteria or viruses. Globally, pneumonia causes more deaths than any 2 Pneumonia other infectious disease. It can often be prevented and can usually be treated. 2 Influenza Update Pneumonia can cause mild to severe illness in 3 people of all ages. Signs of pneumonia can include Communicable Diseases Report coughing, fever, fatigue, nausea, vomiting, rapid breathing or shortness of breath, chills, or chest pain. Certain people that are more likely to become ill with Rabies Awareness pneumonia include adults 65 years of age or older and children younger than 5 4 years. People with underlying medical conditions and those who smoke cigarettes or Sexually Transmitted have asthma are also at increased risk for pneumonia. Diseases Causes of Pneumonia When bacteria, viruses or, rarely, fungi living in your nose, mouth, sinuses, or the (Continued on page 2) Influenza update: 2013-2014 Season s of the week ending November 2, 2013, a total of 7 cases have been A reported in Joplin City (6) and Jasper County (1). Since the beginning of influenza reporting in October, influenza type A represents 85.7 percent of the cases (6 out of 7). This trend shows slightly less reports during the 2013-2014 season when compared with the previous season (2012-2013) within the same period. Influenza virus: Source: CDC.gov (Continued on page 2) Communicable Disease Monthly Newsletter Pneumonia (Continued from page 1) Reduce Your Risk environment spread to your lungs, you can develop Pneumonia can be prevented with vaccines.
  • Kellie ID Emergencies.Pptx

    Kellie ID Emergencies.Pptx

    4/24/11 ID Alert! recognizing rapidly fatal infections Susan M. Kellie, MD, MPH Professor of Medicine Division of Infectious Diseases, UNMSOM Hospital Epidemiologist UNMHSC and NMVAHCS Fever and…. Rash and altered mental status Rash Muscle pain Lymphadenopathy Hypotension Shortness of breath Recent travel Abdominal pain and diarrhea Case 1. The cross-country trucker A 30 year-old trucker driving from Oklahoma to California is hospitalized in Deming with fever and headache He is treated with broad-spectrum antibiotics, but deteriorates with obtundation, low platelet count, and a centrifugal petechial rash and is transferred to UNMH 1 4/24/11 What is your diagnosis? What is the differential diagnosis of fever and headache with petechial rash? (in the US) Tickborne rickettsioses ◦ RMSF Bacteria ◦ Neisseria meningitidis Key diagnosis in this case: “doxycycline deficiency” Key vector-borne rickettsioses treated with doxycycline: RMSF-case-fatality 5-10% ◦ Fever, nausea, vomiting, myalgia, anorexia and headache ◦ Maculopapular rash progresses to petechial after 2-4 days of fever ◦ Occasionally without rash Human granulocytotropic anaplasmosis (HGA): case-fatality<1% Human monocytotropic ehrlichiosis (HME): case fatality 2-3% 2 4/24/11 Lab clues in rickettsioses The total white blood cell (WBC) count is typicallynormal in patients with RMSF, but increased numbers of immature bands are generally observed. Thrombocytopenia, mild elevations in hepatic transaminases, and hyponatremia might be observed with RMSF whereas leukopenia
  • Weekly Epidemiologic L Report

    Weekly Epidemiologic L Report

    WEEKLY EPIDEMIOLOGICAL REPORT A publication of the Epidemiology Unit Ministry of Health 231, de Saram Place, Colombo 01000, Sri Lanka Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: [email protected] Epidemiologist: +94 11 2681548, E mail: [email protected] Web: http://www.epid.gov.lk Vol. 42 No. 33 08 th – 14 th August 2015 Melioidosis Key facts the area. People acquire the disease by inhaling dust contaminated by the bacteria and when the • Melioidosis is an infectious disease caused contaminated soil comes in contact with abraded by a bacterium, Burkholderia pseudomallei. (scraped) area of the skin. Infection most com- • Melioidosis infection commonly involves the monly occurs during the rainy season. lungs. Symptoms • Melioidosis is diagnosed with the help of Melioidosis symptoms most commonly stem blood, urine, sputum, or skin-lesion testing. from lung disease where the infection can form a • Melioidosis is treated with antibiotics. cavity of pus (abscess). The effects can range from mild bronchitis to severe pneumonia. As a • The overall mortality rate is 40%. result, patients also may experience fever, head- Introduction ache, loss of appetite, cough, chest pain, and general muscle soreness. Melioidosis, also called Whitmore's Disease, is an infectious disease caused by a bacterium The effects can also be localized to infection on called Burkholderia pseudomallei (previously the skin (cellulitis) with associated fever and muscle aches. It can spread from the skin known as Pseudomonas pseudomallei-Gram- negative,oxidase positive bacillus). The bacteria are found in contaminated water and soil and spread to humans and animals through direct contact with the contaminated source.
  • Reportable Diseases and Conditions

    Reportable Diseases and Conditions

    KINGS COUNTY DEPARTMENT of PUBLIC HEALTH 330 CAMPUS DRIVE, HANFORD, CA 93230 REPORTABLE DISEASES AND CONDITIONS Title 17, California Code of Regulations, §2500, requires that known or suspected cases of any of the diseases or conditions listed below are to be reported to the local health jurisdiction within the specified time frame: REPORT IMMEDIATELY BY PHONE During Business Hours: (559) 852-2579 After Hours: (559) 852-2720 for Immediate Reportable Disease and Conditions Anthrax Escherichia coli: Shiga Toxin producing (STEC), Rabies (Specify Human or Animal) Botulism (Specify Infant, Foodborne, Wound, Other) including E. coli O157:H7 Scrombroid Fish Poisoning Brucellosis, Human Flavivirus Infection of Undetermined Species Shiga Toxin (Detected in Feces) Cholera Foodborne Disease (2 or More Cases) Smallpox (Variola) Ciguatera Fish Poisoning Hemolytic Uremic Syndrome Tularemia, human Dengue Virus Infection Influenza, Novel Strains, Human Viral Hemorrhagic Fever (Crimean-Congo, Ebola, Diphtheria Measles (Rubeola) Lassa, and Marburg Viruses) Domonic Acid Poisoning (Amnesic Shellfish Meningococcal Infections Yellow Fever Poisoning) Novel Virus Infection with Pandemic Potential Zika Virus Infection Paralytic Shellfish Poisoning Plague (Specify Human or Animal) Immediately report the occurrence of any unusual disease OR outbreaks of any disease. REPORT BY PHONE, FAX, MAIL WITHIN ONE (1) WORKING DAY Phone: (559) 852-2579 Fax: (559) 589-0482 Mail: 330 Campus Drive, Hanford 93230 Conditions may also be reported electronically via the California
  • NCTC) Bacterial Strain Equivalents to American Type Culture Collection (ATCC) Bacterial Strains

    NCTC) Bacterial Strain Equivalents to American Type Culture Collection (ATCC) Bacterial Strains

    This list shows National Collection of Type Cultures (NCTC) bacterial strain equivalents to American Type Culture Collection (ATCC) bacterial strains. NCTC Number CurrentName ATCC Number NCTC 7212 Acetobacter pasteurianus ATCC 23761 NCTC 10138 Acholeplasma axanthum ATCC 25176 NCTC 10171 Acholeplasma equifetale ATCC 29724 NCTC 10128 Acholeplasma granularum ATCC 19168 NCTC 10172 Acholeplasma hippikon ATCC 29725 NCTC 10116 Acholeplasma laidlawii ATCC 23206 NCTC 10134 Acholeplasma modicum ATCC 29102 NCTC 10188 Acholeplasma morum ATCC 33211 NCTC 10150 Acholeplasma oculi ATCC 27350 NCTC 10198 Acholeplasma parvum ATCC 29892 NCTC 8582 Achromobacter denitrificans ATCC 15173 NCTC 10309 Achromobacter metalcaligenes ATCC 17910 NCTC 10807 Achromobacter xylosoxidans subsp. xylosoxidans ATCC 27061 NCTC 10808 Achromobacter xylosoxidans subsp. xylosoxidans ATCC 17062 NCTC 10809 Achromobacter xylosoxidans subsp. xylosoxidans ATCC 27063 NCTC 12156 Acinetobacter baumannii ATCC 19606 NCTC 10303 Acinetobacter baumannii ATCC 17904 NCTC 7844 Acinetobacter calcoaceticus ATCC 15308 NCTC 12983 Acinetobacter calcoaceticus ATCC 23055 NCTC 8102 acinetobacter dna group 13 ATCC 17903 NCTC 10304 Acinetobacter genospecies 13 ATCC 17905 NCTC 10306 Acinetobacter haemolyticus ATCC 17907 NCTC 10305 Acinetobacter haemolyticus subsp haemolyticus ATCC 17906 NCTC 10308 Acinetobacter johnsonii ATCC 17909 NCTC 10307 Acinetobacter junii ATCC 17908 NCTC 5866 Acinetobacter lwoffii ATCC 15309 NCTC 12870 Actinobacillus delphinicola ATCC 700179 NCTC 8529 Actinobacillus equuli ATCC 19392
  • Legionella Gresilensis Sp. Nov. and Legionella Beliardensis Sp. Nov., Isolated from Water in France

    Legionella Gresilensis Sp. Nov. and Legionella Beliardensis Sp. Nov., Isolated from Water in France

    International Journal of Systematic and Evolutionary Microbiology (2001), 51, 1949–1957 Printed in Great Britain Legionella gresilensis sp. nov. and Legionella beliardensis sp. nov., isolated from water in France 1 Centre National de Franc: ois Lo Presti,1‡ Serge Riffard,1 He! le' ne Meugnier,1 Re! fe! rence des Legionella 1 2 3 UPRES EA1655, Faculte! de Monique Reyrolle, Yves Lasne, † Patrick A. D. Grimont, Me! decine RTH Laennec, Francine Grimont,3 Robert F. Benson,4 Don J. Brenner,4 Rue Guillaume Paradin, 4 1 1 69372 Lyon cedex 08, Arnold G. Steigerwalt, Jerome Etienne and Jean Freney France 2 Laboratoire des Author for correspondence: Franc: ois Lo Presti. Tel: j33 0 169 79 79 60. Fax: j33 0 169 79 79 20. Radioisotopes et de e-mail: Francois.Lo-Presti!sanofi-synthelabo.com Biochimie mole! culaire, Ho# pital Edouard Herriot, ! ! 69437 Lyon cedex 03, Novel Legionella-like isolates, strains Montbeliard A1T and Greoux 11 D13T, France isolated from two different French water sources, were studied taxonomically 3 Unite! des Ente! robacte! ries, and phylogenetically. Morphological and biochemical characterization revealed Institut Pasteur, 75724 Paris cedex 15, France that they were Gram-negative, aerobic, non-spore-forming bacilli with a cut- glass appearance that grew only on L-cysteine-supplemented buffered charcoal 4 Respiratory Diseases Branch, Meningitis and yeast extract agar. Phenotypic characterization using fatty acid and ubiquinone Special Pathogens Branch, profiles and SDS-PAGE analysis confirmed that they were closely related, but National Center for distinct from, other species of the genus Legionella, since serotyping could not Infectious Diseases, Centers for Disease Control and relate them to any existing serogroup.
  • Pearls: Infectious Diseases

    Pearls: Infectious Diseases

    Pearls: Infectious Diseases Karen L. Roos, M.D.1 ABSTRACT Neurologists have a great deal of knowledge of the classic signs of central nervous system infectious diseases. After years of taking care of patients with infectious diseases, several symptoms, signs, and cerebrospinal fluid abnormalities have been identified that are helpful time and time again in determining the etiological agent. These lessons, learned at the bedside, are reviewed in this article. KEYWORDS: Herpes simplex virus, Lyme disease, meningitis, viral encephalitis CLINICAL MANIFESTATIONS does not have an altered level of consciousness, sei- zures, or focal neurologic deficits. Although the ‘‘classic triad’’ of bacterial meningitis is The rash of a viral exanthema typically involves the fever, headache, and nuchal rigidity, vomiting is a face and chest first then spreads to the arms and legs. common early symptom. Suspect bacterial meningitis This can be an important clue in the patient with in the patient with fever, headache, lethargy, and headache, fever, and stiff neck that the meningitis is vomiting (without diarrhea). Patients may also com- due to echovirus or coxsackievirus. plain of photophobia. An altered level of conscious- Suspect tuberculous meningitis in the patient with ness that begins with lethargy and progresses to stupor either several weeks of headache, fever, and night during the emergency evaluation of the patient is sweats or a fulminant presentation with fever, altered characteristic of bacterial meningitis. mental status, and focal neurologic deficits. Fever (temperature 388C[100.48F]) is present in An Ixodes tick must be attached to the skin for at least 84% of adults with bacterial meningitis and in 80 to 24 hours to transmit infection with the spirochete 1–3 94% of children with bacterial meningitis.
  • Legionella Shows a Diverse Secondary Metabolism Dependent on a Broad Spectrum Sfp-Type Phosphopantetheinyl Transferase

    Legionella Shows a Diverse Secondary Metabolism Dependent on a Broad Spectrum Sfp-Type Phosphopantetheinyl Transferase

    Legionella shows a diverse secondary metabolism dependent on a broad spectrum Sfp-type phosphopantetheinyl transferase Nicholas J. Tobias1, Tilman Ahrendt1, Ursula Schell2, Melissa Miltenberger1, Hubert Hilbi2,3 and Helge B. Bode1,4 1 Fachbereich Biowissenschaften, Merck Stiftungsprofessur fu¨r Molekulare Biotechnologie, Goethe Universita¨t, Frankfurt am Main, Germany 2 Max von Pettenkofer Institute, Ludwig-Maximilians-Universita¨tMu¨nchen, Munich, Germany 3 Institute of Medical Microbiology, University of Zu¨rich, Zu¨rich, Switzerland 4 Buchmann Institute for Molecular Life Sciences, Goethe Universita¨t, Frankfurt am Main, Germany ABSTRACT Several members of the genus Legionella cause Legionnaires’ disease, a potentially debilitating form of pneumonia. Studies frequently focus on the abundant number of virulence factors present in this genus. However, what is often overlooked is the role of secondary metabolites from Legionella. Following whole genome sequencing, we assembled and annotated the Legionella parisiensis DSM 19216 genome. Together with 14 other members of the Legionella, we performed comparative genomics and analysed the secondary metabolite potential of each strain. We found that Legionella contains a huge variety of biosynthetic gene clusters (BGCs) that are potentially making a significant number of novel natural products with undefined function. Surprisingly, only a single Sfp-like phosphopantetheinyl transferase is found in all Legionella strains analyzed that might be responsible for the activation of all carrier proteins in primary (fatty acid biosynthesis) and secondary metabolism (polyketide and non-ribosomal peptide synthesis). Using conserved active site motifs, we predict Submitted 29 June 2016 some novel compounds that are probably involved in cell-cell communication, Accepted 25 October 2016 Published 24 November 2016 differing to known communication systems.
  • Legionella Survey in the Plumbing System of a Sparse Academic Campus: a Case Study at the University of Perugia

    Legionella Survey in the Plumbing System of a Sparse Academic Campus: a Case Study at the University of Perugia

    Article Legionella Survey in the Plumbing System of a Sparse Academic Campus: A Case Study at the University of Perugia Ermanno Federici 1,*, Silvia Meniconi 2, Elisa Ceci 1, Elisa Mazzetti 2, Chiara Casagrande 1, Elena Montalbani 1, Stefania Businelli 3, Tatiana Mariani 3, Paolo Mugnaioli 3, Giovanni Cenci 1 and Bruno Brunone 2 1 Dipartimento di Chimica, Biologia e Biotecnologie, University of Perugia, 06123 Perugia, Italy; [email protected] (E.C.); [email protected] (C.C.); [email protected] (E.M.); [email protected] (G.C.) 2 Dipartimento di Ingegneria Civile ed Ambientale, University of Perugia, 06123 Perugia, Italy; [email protected] (S.M.); [email protected] (E.M.); [email protected] (B.B.) 3 Ripartizione Tecnica, University of Perugia, 06123 Perugia, Italy; [email protected] (S.B.); [email protected] (T.M.); [email protected] (P.M.) * Correspondence: [email protected]; Tel.: +39-075-5857330 Received: 30 June 2017; Accepted: 29 August 2017; Published: 1 September 2017 Abstract: We have monitored the presence of bacteria belonging to the genus Legionella in the plumbing of buildings at the University of Perugia (Italy). More than 300 water samples were collected from 156 control-point taps in 41 buildings comprised in the eight campuses of the University. Legionella was absent in most samples, while it was found in only 12 buildings (29% of the total). Molecular analysis indicated the presence of L. pneumophila (serogroups 1, 8 and 6–10), L. taurinensis and L. anisa. In only three cases contamination levels were above the limit at which remedial actions are required, according to international guidelines.
  • Animal Biosafety Level

    Animal Biosafety Level

    Biological Safety Manual Prepared by: Environmental Health and Safety Office April 2012 Table of Contents Table of Contents .................................................................................................................... ii Tables and Figures ................................................................................................................. vii Acronyms ........................................................................................................................... viii Foreword ............................................................................................................................... x Document History .................................................................................................................... x 1.0 Introduction ........................................................................................................ 1-1 1.1 Biological Material ............................................................................................. 1-1 1.1.1 Biohazardous Material ........................................................................................ 1-1 1.1.2 Nonbiohazardous Material .................................................................................. 1-2 1.2 Regulations, Guidelines, and Permit Requirements ............................................. 1-2 1.3 Roles and Responsibilities ................................................................................... 1-4 1.3.1 Vice President for Research and Economic Development
  • Metatranscriptomic Analysis of Community Structure And

    Metatranscriptomic Analysis of Community Structure And

    School of Environmental Sciences Metatranscriptomic analysis of community structure and metabolism of the rhizosphere microbiome by Thomas Richard Turner Submitted in partial fulfilment of the requirement for the degree of Doctor of Philosophy, September 2013 This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with the author and that use of any information derived there from must be in accordance with current UK Copyright Law. In addition, any quotation or extract must include full attribution. i Declaration I declare that this is an account of my own research and has not been submitted for a degree at any other university. The use of material from other sources has been properly and fully acknowledged, where appropriate. Thomas Richard Turner ii Acknowledgements I would like to thank my supervisors, Phil Poole and Alastair Grant, for their continued support and guidance over the past four years. I’m grateful to all members of my lab, both past and present, for advice and friendship. Graham Hood, I don’t know how we put up with each other, but I don’t think I could have done this without you. Cheers Salt! KK, thank you for all your help in the lab, and for Uma’s biryanis! Andrzej Tkatcz, thanks for the useful discussions about our projects. Alison East, thank you for all your support, particularly ensuring Graham and I did not kill each other. I’m grateful to Allan Downie and Colin Murrell for advice. For sequencing support, I’d like to thank TGAC, particularly Darren Heavens, Sophie Janacek, Kirsten McKlay and Melanie Febrer, as well as John Walshaw, Mark Alston and David Swarbreck for bioinformatic support.